VEEDA CLINICAL RESEARCH LIMITED IPO

About Veeda Clinical Research Limited

Veeda Clinical Research has filed a draught red herring prospectus (DRHP) with SEBI in order to seek funds through an IPO. The fresh issuance would consist of up to Rs 331.60 crore in new equity shares and a Rs 500 crore offer for sale (OFS) by the founders and current shareholders.CX Alternative Investment Fund may invest up to Rs 8.08 crore, Arabelle Financial Services Limited may invest up to Rs 90.19 crore, Bondway Investment Inc. may invest up to Rs 259.77 crore, Stevey International Corporation may invest up to Rs 0.04 crore, and Basil Private Limited may invest up to Rs 141.93 crore in the OFS. The issue's book running lead managers are SBI Capital Markets Limited, ICICI Securities Limited, JM Financial Limited, and Systematix Corporate Services Limited.

Veeda Clinical Research Limited provides a wide range of services to clients in North America, Europe, and Asia, covering most parts of the drug development and launch value chain. Specialized in bioanalytical services, such as bioavailability and bioequivalence ("BA & BE") investigations, as well as a comprehensive suite of clinical trials, including pre-clinical, early phase, and late phase clinical trials, as well as associated services, are available. They have experience in pharmacokinetics ("PK") studies as well as generic, novel chemical entities ("NCEs"), big molecules, and biosimilars trials. As of March 31, 2021, they have expanded from a single facility in Ahmedabad with a total capacity of 62 beds and a monthly capacity of 7,000 samples to four facilities in Ahmedabad and one in Mehsana with a total capacity of 532 beds and a monthly capacity of 100,000 samples. They currently have pre-clinical trial capabilities with two facilities in Bangalore, each with 99 distinct experiment rooms tailored to international standards and self-contained chemistry, biopharmaceutical, and analytical laboratories.

Veeda Clinical Research Limited IPO Objectives:

Here are a few quick reasons why Veeda Clinical Research Limited going public: 

• Repayment/prepayment of certain indebtedness (including accrued interest) availed by our Subsidiary,Bioneeds.
• Funding capital expenditure requirements of the Company.
• Investment in the Subsidiary, Bioneeds for financing capital expenditure requirements.
• Funding further acquisition of equity shares of Bioneeds.
• Investment in the Joint Venture, Ingenuity BioSciences Private Limited through acquisition of equityshares.
• Funding working capital requirements of the Company.

Why should you invest in Veeda Clinical Research Limited IPO?

• One of the largest independent full-service CROs in India with recent Increase in their presence across regulated markets in the US and the EU.
• Indian CRO market captures about 3% of the global market share by value, estimated at USD 2 Bn in 2021 and is expected to be the fastest growing market with a CAGR of about 12% from 2021 to 2026.

Veeda Clinical Research Limited Noteworthy Highlights:

1. For Fiscal 2021, the company performed research for 157 customers, including some of the worlds largest and astest growing pharmaceutical firms.
2. By combining their previous experience, knowledge of the worldwide pharma business and significant scientific expertise, they are one of the leaders in providing clinical research services to their global clients in 27 countries across Europe, Asia and North America in an efficient and safe manner.
3. The company has built 45 Bioanalytical systems throughout the facilities to help them provide effective bioanalytical services, with a monthly processing capacity of 100,000 samples.